Cue Biopharma, Inc. (CUE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on August 16, 2024, regarding an event that occurred on August 15, 2024. The Company is a biopharmaceutical entity incorporated in Delaware with its principal executive offices in Boston, Massachusetts. Its common stock trades on The Nasdaq Capital Market under the symbol "CUE."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes and Events
On August 15, 2024, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department. The notice stated that for the last 30 consecutive business days, the closing bid price of the Company's common stock had been below $1.00 per share, failing to meet the Minimum Bid Requirement under Nasdaq Listing Rule 5550(a)(2). This notice has no immediate effect on the listing status of the stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has an initial 180-calendar-day period, expiring on February 11, 2025, to regain compliance.
- Requirements: To comply, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days within the 180-day window.
- Secondary Compliance: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period, provided it meets other listing standards (excluding the bid price) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- Risks: There is no assurance the Company will regain compliance. Failure to do so could lead to delisting. While the Company may appeal a delisting determination to a Hearings Panel, success is not guaranteed.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of CUE stock to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the Company's intent to effect a reverse stock split if the initial compliance period is insufficient.
- Review the Company's cash position in subsequent filings (10-Q or 10-K) to determine if liquidity constraints impact the ability to maintain operations or execute a reverse split.
- Track the 180-day compliance deadline of February 11, 2025.